Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype

Sexually Transmitted Infections

Volumn 77, Issue 4, 2001, Pages 283-286

  Shahmanesh, M ^a   Jaleel, H ^a   DeSilva, Y ^a   Ross, J D C ^a   Caslake, M ^b   Cramb, R ^b  

^a SELLY OAK HOSPITAL   (United Kingdom)

^b Department of Clinical Biochemistry ^*  (United Kingdom)

Author keywords

Apolipoprotein E; HIV; Hyperlipidaemia; Protease inhibitors

Indexed keywords

APOLIPOPROTEIN E2; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LIPOPROTEIN RECEPTOR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG INDUCED DISEASE; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPOPROTEINEMIA TYPE 3; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEINS E; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ELECTROPHORESIS, AGAR GEL; FEMALE; HIV INFECTIONS; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; MALE; MIDDLE AGED; PHENOTYPE; PROTEASE INHIBITORS; PROTEIN ISOFORMS;

EID: 0034918425     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.77.4.283     Document Type: Article

References (26)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1infected patients
3. Visceral abdominal-fat accumulation associated with the use of indinavir
4. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
5. Hyperlipidaemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment
6. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
7. Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors
8. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
9. Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors
10. A rapid micromethod for apolipoprotein E phenotyping directly in serum
11. Hypertriglyceridaemia in the acquired immunodeficiency syndrome
12. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection
13. Mitochondrial toxicity in HIV
14. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations
15. Use of HIV protease inhibitors is associated with endothelial dysfunction
16. Pathogenesis of HIV-protease inhibitor associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance
17. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
18. Type III hyperlipoproteinaemia. An analysis of two contemporary definitions
19. Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy
20. Triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol: A meta analysis of population-based prospective studies
21. Lipoprotein Lp(a) and the risk of myocardial infarction
22. Joint British recommendations on prevention of coronary heart disease in clinical practice
23. Why switch from protease inhibitors (PI) to non-nucleoside reverse transcriptase inhibitors (NNRTI)
24. Risk and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
25. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities